Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||DTRMWXHS-12 + Everolimus|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DTRMWXHS-12||DTRM-12|DTRMWXHS 12||BTK inhibitor 22||DTRMWXHS-12 inhibits BTK, resulting in decreased B-cell receptor (BCR) signaling and potentially leading to reduced tumor cell growth (NCI Drug Dictionary).|
|Everolimus||Afinitor||RAD001|Zortress||mTORC1 Inhibitor 8||Afinitor (everolimus) binds to FKBP-12 and allosterically inhibits mTOR, leading to decreased mTORC1 signaling and potentially resulting in decreased tumor cell growth (PMID: 17766661, PMID: 28400999). Afinitor (everolimus) is FDA approved for use in neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, in adult and pediatric patients aged 1 year and older with tuberous sclerosis complex who have subependymal giant cell astrocytoma, and in combination with Aromasin (exemestane) in hormone receptor-positive, HER2-negative breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02900716||Phase I||DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus||Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas||Recruiting|